Overview
A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2026-08-01
2026-08-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C. VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Verve Therapeutics, Inc.
Criteria
Inclusion Criteria:- Diagnosis of HeFH or premature CAD
- Females of non-childbearing potential or males
Exclusion Criteria:
- Homozygous familial hypercholesterolemia
- Active or history of chronic liver disease
- Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol